+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06028074

Open-Label Phase 12 Study of Intravenous GIM-122 to Evaluate Safety and Antitumor Activity in Adults with Advanced Solid Tumors

Led by Georgiamune Inc · Updated on 2026-08-17

111

Participants Needed

11

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating GIM-122, a first-in-class, humanized monoclonal antibody, in adults with advanced solid tumors. The study is a Phase 12 open-label trial designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of intravenous GIM-122. This trial includes dose escalation and expansion phases to find the recommended dose and evaluate effectiveness. Participants receive GIM-122 through intravenous administration either every 2 or 3 weeks. The study consists of two parts Part A focuses on dose escalation and enrichment, while Part B involves dose optimization and cohort expansion at the recommended Phase 2 dose. The treatment is given as a single agent, and dosing schedules depend on the assigned cohort. During the study, participants undergo various assessments including laboratory tests, imaging scans, and evaluations of tumor response using RECIST criteria. Researchers monitor dose-limiting toxicities, adverse events, pharmacokinetic parameters, and anti-tumor activity over time. The study duration includes up to 18 months for initial safety and dose finding, with follow-up up to 36 months to evaluate clinical outcomes and tolerability.

CONDITIONS

Brief Title

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

Research Team

L

LumaBridge CRO

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here